# US 2013/0281377 A1 · Treating multiple myeloma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281377 A1
- Document ID: US20130281377A1
- Status: Published application
- Kind: A1
- Application number: 13/995,623
- Filed: 2011-12-22
- Published: 2013-10-24
- Earliest claimed: 2010-12-23
- Assignees: Mayo Foundation for Medical Education and Research
- Inventors: Rafael Fonseca; Alexander Keith Stewart; Peter Bergsagel; Marta Chesi
- Web page: https://patentgrep.com/patent/US20130281377A1

## CPC

- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This document relates to methods and materials for treating multiple myeloma. For example, methods and materials for using albumin-bound paclitaxel composition (e.g., Abraxane®, a paclitaxel albumin-stabilized nanoparticle formulation) to treat multiple myeloma are provided.

## Claims

### Claim 1

A method for treating a human having multiple myeloma, wherein said method comprises administering, to said human, an albumin-bound paclitaxel composition under conditions wherein the number of multiple myeloma cells within said human is reduced.

### Claim 2 (depends on 1)

The method of claim 1, wherein between about 50 mg and 150 mg of said composition is administered.

### Claim 3 (depends on 1)

The method of claim 1, wherein said composition is administered at least once a week for at least three weeks.

### Claim 4 (depends on 1)

The method of claim 1, wherein said composition is administered under conditions wherein the number of multiple myeloma cells within said human is reduced by greater than 10 percent.

### Claim 5 (depends on 1)

The method of claim 1, wherein said composition is administered under conditions wherein the number of multiple myeloma cells within said human is reduced by greater than 20 percent.

### Claim 6 (depends on 1)

The method of claim 1, wherein between about 90 mg and 110 mg of said composition per m2 is administered.

### Claim 7

A method for treating a human having multiple myeloma, wherein said method comprises administering, to said human, an albumin-bound paclitaxel composition under conditions wherein the level of free lambda light chain polypeptides in the blood of said human is reduced.

### Claim 8 (depends on 7)

The method of claim 7, wherein between about 50 mg and 150 mg of said composition is administered.

### Claim 9 (depends on 7)

The method of claim 7, wherein said composition is administered at least once a week for at least three weeks.

### Claim 10 (depends on 7)

The method of claim 7, wherein said composition is administered under conditions wherein the level of free lambda light chain polypeptides in the blood of said human is reduced by greater than 10 percent.

### Claim 11 (depends on 7)

The method of claim 7, wherein said composition is administered under conditions wherein the level of free lambda light chain polypeptides in the blood of said human is reduced by greater than 20 percent.

### Claim 12 (depends on 7)

The method of claim 7, wherein between about 90 mg and 110 mg of said composition per m2 is administered.

### Claim 13

A method for treating a human having multiple myeloma, wherein said method comprises administering, to said human, an albumin-bound paclitaxel composition under conditions wherein the level of IgA in the blood of said human is reduced.

### Claim 14 (depends on 13)

The method of claim 13, wherein between about 50 mg and 150 mg of said composition is administered.

### Claim 15 (depends on 13)

The method of claim 13, wherein said composition is administered at least once a week for at least three weeks.

### Claim 16 (depends on 13)

The method of claim 13, wherein said composition is administered under conditions wherein the level of IgA in the blood of said human is reduced by greater than 10 percent.

### Claim 17 (depends on 13)

The method of claim 13, wherein said composition is administered under conditions wherein the level of IgA in the blood of said human is reduced by greater than 20 percent.

### Claim 18 (depends on 13)

The method of claim 13, wherein between about 90 mg and 110 mg of said composition per m2 is administered.
